NPPB and atrial fibrillation: Moreover, the effectiveness of NT-proBNP as a surrogate endpoint may be complicated by patient comorbidities, as demonstrated in the ASTRONAUT trial, where the ability of aliskiren to lower NT-proBNP varied based on the presence of atrial fibrillation and flutter [98].